Cargando…
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
Definitions of platinum resistance have been questioned and changed over the last five years, even though no predictive biomarker of resistance exists. These have sculpted how we approach platinum retreatment and, consequently, how we devise new treatment strategies for those patients with tumour pr...
Autores principales: | Flynn, Michael J., Ledermann, Jonathan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255242/ https://www.ncbi.nlm.nih.gov/pubmed/35800366 http://dx.doi.org/10.20517/cdr.2022.13 |
Ejemplares similares
-
Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
por: Rose, Peter G.
Publicado: (2022) -
Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022) -
Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022) -
PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021) -
Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)